Menu
Back to Journals » ClinicoEconomics and Outcomes Research » Volume 9
Original Research
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 22,584 | Dovepress* | 21,160+ | 2,019 | 23,179 | |
| PubMed Central* | 1,424 | 464 | 1,888 | ||
| Totals | 22,584 | 2,483 | 25,067 | ||
| *Since 30 December 2016 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 2 | 0 | 0 | 0 | 0 | 2 |
View citations on PubMed Central and Google Scholar